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Amiodarone therapy in adults with congenital heart disease (CHD) is associated with a signiﬁcant risk of amiodarone-induced
thyrotoxicosis (AIT). We developed a risk index to identify those patients being considered for amiodarone treatment who are at
high risk for AIT. We reviewed the health records of adults with CHD and assessed the association between potential clinical
predictors and AIT. Signiﬁcant predictors were included in multivariate analyses. The parameter estimates from multivariate
analysis were subsequently used to develop a risk index. 169 adults met eligibility criteria and 23 developed AIT. The ﬁnal model
included age, cyanotic heart disease and BMI. The risk index developed identiﬁed 3 categories of risk. Their AIT likelihood ratios
were: 0.37 for low risk (95% CI 0.15–0.92); 1.12 for medium risk (95% CI 0.65–1.91); and 3.47 for high risk (95% CI 1.7–7.11).
The AIT predicted risk in our population was 5% for the low risk group, 15% for the medium risk group and 47% for the high
risk group. Conclusions. We derived the ﬁrst model to quantify the risk for developing AIT among adults with CHD. Before using
it clinically to help selecting among alternative antiarrhythmic options, it needs validation in an independent population.
1.Introduction
In the United States, the population of adults with congenital
heart disease (CHD) is estimated at approximately 1 million,
[1, 2], and the prevalence of those with complex CHD
is growing at a rate of about 5% per year [1]. These
individuals experience tachyarrhythmias, mainly atrial, at
> 20% prevalence with more than double the risk of adverse
events (stroke, heart failure) compared to those without
arrhythmia [3]. The most commonly used therapies are
radiofrequency ablation (RFA) and antiarrhythmic drugs.
Unfortunately RFA is often made diﬃcult by the complex
cardiac anatomy of these patients, and antiarrhythmic med-
ications carry signiﬁcant risks associated with the speciﬁc
medications used. Negative inotropic action, a common
side eﬀect of antiarrhythmic medications, is potentially
harmful to patients with impaired ventricular function. For
many of these patients with moderate and complex CHD,
maintenance of sinus rhythm is essential [4].
Amiodarone is one of the agents with very good eﬃ-
cacy for arrhythmia control and is hemodynamically well
tolerated by patients with impaired inotrope function and/or
preexistent hypotension. Amiodarone, however, is associated
with a number of side eﬀects [5] including amiodarone-
induced thyrotoxicosis (AIT). Given the morbidity and
mortality associated with AIT [6], a clinical risk index that
would inform clinicians and their patients regarding the
probability of developing AIT could prove clinically useful,
enabling risk-informed decision making. (See supplemen-
tary available online at doi:10.1155/2012/210529 for two
cases scenarios that illustrate the potential utility of an AIT
risk index). In this study we sought to develop an AIT risk
index for use in CHD patients with tachyarrhythmias who
are being considered for amiodarone therapy.2 Journal of Thyroid Research
2. Methods
2.1. Study Design and Setting. We conducted a single-center
health records review of consecutive patients presenting to
the adult CHD clinic at Mayo Clinic Rochester. The Mayo
Clinic Institutional Review Board approved the protocol
without the need for informed consent. Records of patients
who had not given prior authorization to have their medical
records reviewed for research purposes were excluded in
compliance with Minnesota Statute. The authors of this
manuscript have certiﬁed that they comply with the Princi-
ples of Ethical Publishing [7].
2.2. Database Used. From the database of Adult CHD
Clinic at Mayo Clinic Rochester, we identiﬁed a cohort of
CHD patients treated with amiodarone during the period
1987–2009. The Adult CHD Clinic is an academic tertiary
referral practice, and the database contains demographic
information, diagnoses, and medication lists for all patients
with CHD seen in the Clinic. A team of 6 trained nurse
abstractors, blinded as to patient outcome, abstracted addi-
tionaldatafrompatients’electronicandpaperhealthrecords
using a standardized data abstraction form. The nurse
abstractors were trained by means of a 1-hour training
session, and periodic meetings were held thereafter with
the lead investigator (M. N. Stan) to address any questions
that arose during the abstraction process. To validate the
abstracting procedure, the lead abstractor (“gold standard”)
reabstracted a random sample of 10 patients. We identiﬁed
24 diﬀerences in the 330 values reviewed indicating that the
abstracting process had an acceptable accuracy of 92.7%.
2.3. Patient Selection and Timing of Follow-Up Assessment.
From the complete database (4,883 patients), we selected for
further study patients who received amiodarone for a mini-
mum of 90 days and had no prior history of hyperthyroidism
or thyroidectomy. We followed the patients until their ﬁnal
thyroid evaluation on amiodarone or until they developed
AIT.
2.4. Outcome Measures and Deﬁnitions. AIT was deﬁned as
suppressed TSH with an elevated or normal T4 and/or T3
in the outpatient setting or suppressed TSH with elevated
T4 and/or T3 in the inpatient setting with the exclusion of
sick euthyroid and/or drug eﬀects (i.e., heparin, dopamine,
and glucocorticoids). Investigators assessed for this outcome
unaware of which features would be selected for predictor
variables. The two criteria to be met for AIT type 2 were
[8, 9] (a) absence of nodular goiter or presence of small
diﬀuse goiter with negative thyroid antibodies and (b) RAI
uptake <3% and low vascularity on thyroid Doppler ﬂow
(if only one investigation was available, it was accepted as
suﬃcient for this criteria). If one of these criteria was not
met, the AIT was deﬁned as type 1. If there was not suﬃcient
information to make this determination, the AIT was labeled
as “undeﬁned.” Cyanotic CHD was deﬁned as a congenital
heart anomaly with a right-to-left shunt that either did not
undergo surgical repair or had an incomplete or palliative
repair prior to amiodarone therapy.
2.5. Statistical Analysis. Summary statistics for the continu-
ous variables were expressed as mean and standard deviation
(SD) or median with interquartile range (IQR), depending
on the normalcy of distribution. Categorical variables were
summarized as percentages. Comparison between groups
was based on a two-sample t-test for continuous variables
and Pearson’s chi square test for categorical variables. Bivari-
ate and multivariate predictors of AIT development were
assessed with the Cox proportional hazard model using SAS
softwareversion9.2.Resultsoftheanalysesweresummarized
as relative risk (RR), hazard ratio (HR), and likelihood ratio
(LR) with their 95% conﬁdence intervals (CI) and P-values.
To address the skewed distribution for BMI, ordinal levels
werecomputedforthemultivariateanalysis,assigninglowest
level for the high BMI subgroup. P values were reported with
3 digits if <0.1.
3. Results
We identiﬁed 23 AIT cases from the cohort of 169 CHD
patients. The median follow-up period was 3.1 years (IQR
1.5–6.7years).Therewere2patientsforwhomBMIanddose
of amiodarone were not available, leaving 167 patients for
inclusion in the risk factor analysis.
In these analyses the 2 clinical AIT subgroups (type 1
with 7 patients and type 2 with 13 patients) had similar
BMI at initiation of amiodarone (type 1: mean BMI 22.2,
SD 3.4; type 2: mean BMI 21.5, SD 3.1; P = 0.71) as
well as with similar gender, age, cyanotic CHD prevalence,
average amiodarone dose, and duration of therapy (P ≥ 0.1
for each). Three cases had an undeﬁned AIT subtype. In
a sensitivity analysis, we assigned them to the most likely
category based on the available data; this did not change
the BMI comparison between the AIT subtypes. Due to
thesesimilarities,allAITsubtypeswerecombinedforfurther
risk factor analysis. Twenty-one variables were assessed for
association with AIT (Table 1).
The variables most likely to be predictive of AIT were
assessed in a bivariate Cox proportional hazard model
(Table 2).
After these bivariate analysis, a number of parameters
were included in the multivariate analysis based on their
resultsin the initial analyses,their biological association with
the outcome, and on associations reported in the literature
(seesupplementaryTable 1).Theseanalyseswerecarriedout
using the Cox proportional hazard method. For this analysis
we selected BMI in the 3 categories (high if >25, normal
f o r2 1t o2 5 ,a n dl o wi f<21), gender, cyanotic status, age at
start of amiodarone therapy, goiter, and average amiodarone
dose mg/kg body weight. Duration of amiodarone therapy
was implicit in the Cox model. In multivariate analyses we
observed BMI in 3 categories (HR estimate 3.2 with 95% CI
= 1.6–6.2) and goiter (HR estimate 5.6 with 95% CI = 2–
16) to be the only independent predictors of AIT. As goiter
was associated only with AIT type 1 in this cohort and itsJournal of Thyroid Research 3
Table 1: Overall cohort and group characteristics (n = 169).
Variable Entire cohort
(n = 169) G r o u pw i t hA I T Group without
AIT P value
Men—n (%) 89 (52.7) 13 (56.5) 76 (52.1) 0.69
Age (years)—mean (SD) 42.7 (14.1) 35.3 (12.2) 43.8 (14.1) 0.006
BMI (kg/m2)—mean (SD) 25.2 (4.9) 22.0 (3.1) 25.8 (4.9) <0.001
Weight (kg)—mean (SD) 69.9 (16.5) 62.2 (11.8) 75.5 (16.5) 0.001
Supraventricular
arrhythmia∗—n (%) 152 (90) 23 (100) 129 (88.4) 0.084
Baseline systolic blood pressure
(mm Hg)—mean (SD) 117 (13) 116 (17.5) 117.2 (12.5) 0.77
Cyanotic CHD diagnosis—n (%) 34 (20.1) 8/23 (34.8) 26/146 (17.8) 0.059
Tricuspid regurgitation—n(%)
Absent
Mild
Moderate
Severe
37 (25)
50 (35)
23 (16)
34 (24)
7 (37)
7 (37)
2 (10.5)
3 (15.8)
30 (24)
43 (34)
21 (16.8)
31 (24.8)
0.17∗∗
Left ventricular ejection fraction
% —mean (SD) 47.5 (13.5) 43 (13.2) 48 (13.4) 0.15
Hematocrit (%)—mean (SD) 42.9 (7.2) 43.5 (4.7) 42.8 (7.5) 0.61
Protein-losing enteropathy—n
(%) 8 (4.8) 0 (0) 8 (5.5) 0.6
Goiter—n (%) 19 (12.9) 7 (35) 12 (9.5) 0.002
Albumin (g/dL)—median (IQR) 4.3 (4.0–4.5) 4.4 (4.2–4.7) 4.3
(4–4.5) 0.13
Average amiodarone dose/day
(mg/day)—median (IQR) 200 (200–300) 200 (200–250) 200 (200–300) 0.77
Average amiodarone dose/kg/day
(mg/kg/day)—median (IQR) 3.04 (2.42–3.87) 3.51 (2.32–3.85) 2.96 (3.05–4.12) 0.015
Time on amiodarone
(days)—median (IQR)
1147
(546–2438)
1066
(849–1470)
1206
(393–2529) 0.79
Cumulative amiodarone
exposure (g/kg)—median (IQR) 3.7 (1.2–7.3) 3.5 (2.7–5.2) 3.8 (1.1–7.3) 0.60
Abnormal liver tests—n (%) 26 (16.5) 2 (8.7) 24 (17.8) 0.27
Abnormal pulmonary function
test—n (%) 67 (84.4)∗∗∗ 14 (100) 53 (81.5) 0.11
Hospital admissions per year on
amiodarone∗∗∗∗—median
(IQR)
0.4 (0.2–1.1) 0.4 (0.1–1.0) 0.6 (0.2–1.1) 0.57
Days in the hospital per year on
amiodarone∗∗∗∗—median
(IQR)
3.4 (1.2–8.0) 2.6 (0.9–6.4) 4.5 (1.7–13.5) 0.15
∗The ventricular arrhythmias treated were ventricular tachycardia, premature ventricular contractions, and ventricular ﬁbrillation.
∗∗P value for trend.
∗∗∗ This variable was available in less than 75% of the entire cohort.
∗∗∗∗ 23 age and gender matched pairs used for this analysis.
BMI: body mass index; CHD: congenital heart disease.
presence usually excludes AIT type 2 [10], it was excluded
from consideration for the ﬁnal model. Age was included
in the ﬁnal model due to its confounding eﬀect on BMI
(Pearson’s correlation r = 0.24 with P = 0.007). Cyanosis
showed a trend for association with BMI in our bivariate
analysis (P = 0.059) and was reported in a similar cohort
to be predictive of AIT [11]. These consistencies along with
itsbiologicalplausibility[12]ledustoincludecyanosisinthe
ﬁnal model. The ﬁnal analysis is displayed in Table 3.
3.1. Baseline Risk Calculator. From the ﬁnal model we devel-
oped an overall AIT risk score at initiation of amiodarone.
This calculation was based on parameter estimates, from the
multivariate Cox proportional hazard model. Based on the
ratio between the parameter estimates, the following method
was used to allocate points for the risk score: 2 points were
allocated for each BMI category increase over category “0”
(i.e., BMI > 25) and 1 point was allocated for patients with
cyanotic CHD (category “1”) in contrast to 0 points for the4 Journal of Thyroid Research
Table 2: Bivariate models for AIT risk prediction (Cox proportional hazard model).
Risk factors Parameter
estimate
P value
(chi square) HR 95% CI of HR (LL, UL)
Age at start of amiodarone −0.026 0.145 0.974 0.941 1.009
Amiodarone dose mg/kg 0.241 0.167 1.272 0.904 1.789
BMI (3 categories) 0.966 0.002 2.627 1.438 4.798
BMI (>25) −1.903 0.002 0.149 0.045 0.499
BMI (21 to 25) (reference =
BMI < 21)
−1.047 0.034 0.351 0.134 0.921
Cyanotic 0.630 0.135 1.878 0.822 4.293
Goiter 1.405 0.003 4.08 1.6 10.3
Gender (reference =
female) 0.019 0.964 1.02 0.45 2.3
BMI: body mass index; CI: conﬁdence interval; HR: hazard ratio; LL: lower limit; UL: upper limit.
Table 3: Final Cox proportional hazards model for development of AIT.
Risk factor of AIT Parameter
estimate
P-value
(chi square)
HR
Estimate 95%
LL
95%
UL
Age −0.02 0.266 0.979 0.942 1.017
Cyanotic (ref:
cyanosis = no) 0.43 0.345 1.536 0.631 3.74
BMI 3 categories (ref: BMI
> 25) 0.83 0.009 2.286 1.226 4.262
noncyanotic patients (category “0”). The range of possible
scores is 0 to 5. The distribution of patients according to
their risk score is presented in supplementary e-Table 2. The
higher the score, the higher the likelihood for that patient to
developAITinthefuture.Themodelgeneratedthefollowing
formula for risk calculation:
AIT Risk prediction index = BMI category × 2
+C y a n o t i cc a t e g o r y× 1.
(1)
The likelihood ratios (LRs) for the diﬀerent levels of risk are
included in Table 4.
Inordertoimprovetheprecisionofourriskestimateand
given the close results observed between consecutive scores,
we combined scores 0 and 1 in the low-risk category, scores 2
and 3 in the medium-risk category, and scores 4 and 5 in the
high-risk category. Using the known cumulative incidence of
AITinaCHDpopulation,onecancalculatetheactualriskof
AIT for a given individual. Starting with a pretest probability
of AIT development of 13.6% (the cumulative incidence in
our population), we calculated a posttest probability of AIT
of 5.0% for the low-risk group, 15.2% for the medium-risk
group, and 47.2% for the high-risk group.
Since AIT development is time dependent, we also
calculated the actual risk for each category in relationship
to the expected time the patient will be on amiodarone
(Figure 1 and see supplemetary e-Table 3).
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Figure 1: Percent survival free of AIT (%) based on length of time
on amiodarone and AIT risk category.
4. Discussion
We developed a risk prediction index that can determine the
likelihood of AIT in adults with CHD. We identiﬁed a cohort
of 169 adults with CHD who were treated with amiodarone
for at least 90 days, among which 23 (13.6%) developed AIT.
Among the 5 variables signiﬁcantly associated with AIT on
univariate analysis, we developed a multivariate model thatJournal of Thyroid Research 5
Table 4: Likelihood ratios according to AIT risk score.
Risk
score P (disease) P (no disease) Likelihood ratio
(95% CI)
Combined
categories
Likelihood ratio
(95% CI)
03 / 2 1 = 14.3% 60/146 = 41.4% 0.34 (0.12–1.01)
Low risk 0.37 (0.15–0.92)
11 / 2 1 = 4.8% 14/146 = 9.6 0.49 (0.07–3.58)
25 / 2 1 = 23.8% 42/146 = 28.8 0.83 (0.37–1.85)
Medium risk 1.12 (0.65–1.91)
34 / 2 1 = 19.0% 14/146 = 9.59 1.98 (0.72–5.47)
43 / 2 1 = 14.3% 8/146 = 5.5% 2.61 (0.75–9.06)
High risk
3.47 (1.70–7.11)
55 / 2 1 = 23.8% 8/146 = 5.5% 4.35 (1.57–12.04)
includes age, cyanosis, and BMI at initiation of amiodarone
to predict an individual patient’s risk of developing AIT.
These variables are simple to collect and readily available in
the outpatient setting. To the best of our knowledge, this
is the ﬁrst study in which a risk prediction index for AIT
in adults with CHD was developed. Our prediction model
requires validation in an independent patient population
before implementation in clinical practice. The potential
utility of the risk calculator is demonstrated in two case
studies attached in the online Appendix.
A number of individual risk factors for AIT have been
identiﬁed in the general population including low-iodine
status [13], male gender [14, 15], and goiter, which was
found to be present in 67% of AIT cases in one series [16].
A speciﬁc risk factor for patients with CHD is cyanotic CHD
status [11] .I no u rc o h o rtw ea l s oi d e n t i ﬁ e dl o wB M Ia sari s k
factor for AIT and noted the confounding eﬀect that age has
on this variable.
The explanation for this novel association likely relates to
the preferential deposition of amiodarone in adipose tissue
combinedwithitsconcentration-dependentcytotoxicity[17,
18] and the current clinical practice of giving a ﬁxed, rather
than a weight-adjusted, dose of amiodarone. We suggest
that the lipophilic character of amiodarone leads to lower
drug exposure (i.e., lower blood and tissue levels) into the
thyroid in obese individuals and to higher drug exposure
(i.e., higher blood and tissue levels) in individuals with
smaller adipose tissue depots, making the latter at higher risk
for AIT. Prospective studies to determine the impact of BMI
on serum and tissue amiodarone levels at steady state are
warranted to further explore this hypothesis.
To date there are no published data that assemble these
various risk factors into a comprehensive risk assessment
indexthatcouldbeusedtogaugeanindividual’sriskforAIT.
The current report represents the ﬁrst risk prediction index
based on variables associated with AIT development in this
population. It is notable that this calculator adds signiﬁcant
information to the risk assessment by adjusting the average
population risk to the individual patient. In doing so, a
patient’s calculated risk may range anywhere between 5.0%
and 47.2% at the extremes of the risk index. If validated,
the results we report as LRs could be used in similar
populations provided that the prevalence of disease can be
estimated. If so LRs can serve to calculate the posttest proba-
bilityofAITforthatpopulation[19].Itisimportanttoreﬁne
the AIT risk because of the high morbidity and mortality
associated with AIT [6]. This risk index could become a
very useful tool in quantifying the individual beneﬁts and
risks associated with amiodarone use and thus supporting
clinical decision making. Identifying a high risk of AIT could
lead to the decision to use a diﬀerent antiarrhythmic agent
without thyroid side eﬀects [20], to attempt cardioversion or
to attempt ablation of the arrhythmogenic focus [21].
In order to construct the instrument, we opted for
Cox proportional hazard analysis as opposed to recursive
partitioning given our aim for high overall accuracy where
both low and high risk for AIT are important outcomes
in our cohort [22]. In order to increase the reproducibility
of our ﬁndings, we used a very clear deﬁnition for the
outcome based on biochemical data. All the parameters
that were selected for the model [23] are either biologically
connected with the outcome (time on amiodarone and age
of patient) and/or have demonstrated association with AIT
in our cohort analysis (BMI and cyanotic status). Some
parametersknowntobeassociatedwithAIT,includinggoiter
and low-iodine status, were not included in this instrument.
Goiter is highly predictive of type 1 AIT and, by deﬁnition,
excludes the identiﬁcation of most AIT type 2 cases. Since
the latter is the dominant form of AIT [10], we have decided
against including goiter in the ﬁnal Cox model since it would
bias the model to calculate a lower risk for those likely to
develop AIT type 2. Low-iodine status as a risk factor for AIT
has been reported in earlier studies [13]. While iodine status
was not speciﬁcally assessed in our population, our cohort
was composed almost exclusively of US residents who are
likely to be iodine suﬃcient [24]. Therefore, our results may
not generalize to an iodine-deﬁcient population.
We believe that our instrument is easy to use given
the limited number of clearly deﬁned, clinically relevant
variables that must be collected. It is also, clinically sensible,
and likely to be incorporated easily into the ﬂow of patient
care. However, it must ﬁrst be validated in an independent6 Journal of Thyroid Research
patient population before it can be used in the clinical
setting.
Our study has a number of limitations. The study design
was a health records review and is susceptible to the
types of biases common to this study design. However, we
took several steps to limit the intrusion of bias into the
data abstraction process including training of data abstrac-
tors, using a standardized data abstraction form, uniform
deﬁnition of important predictor variables, clearly deﬁned
outcomes, assessment of the accuracy of data abstraction,
blinding abstractors as to outcome at the time of predictor
variable assessment and to study hypothesis, blinding inves-
tigators to the predictor variables at the time of the outcome
assessment, and periodic meetings to address questions that
arose in the process of data abstraction. Given the time
required to develop AIT, a health records review design is
the most pragmatic and economically eﬃcient design. We
ascertained the predictor variables age, BMI, and cyanotic
status of the CHD in 167/169 patients from our cohort
(98.8%), minimizing thus the risk of selection bias. There
were also only 23 patients in the cohort who developed AIT,
increasingtheriskofoverﬁttingourmodel.Validationofour
ﬁndings in another cohort of adults with CHD will allow for
reﬁnement and validation of the model. Another limitation
was that we could capture only presence or absence of
goiter, rather than more accurate information concerning
thyroid volume as only a minority of patients in our cohort
underwent thyroid ultrasound. For similar reasons, we were
unable to carry out an analysis addressing the impact of
serum amiodarone levels on the AIT risk, as this parameter
was obtained in only approximately 10% of the cohort.
Futureprospectivestudieswillbetterquantifytheseelements
and allow full exploration of mechanisms underlying our
ﬁndings.
In conclusion our results provide for the ﬁrst time a
quantiﬁcation of the risk of AIT in amiodarone-treated
adults with CHD. The identiﬁcation of patients at high
risk for AIT could lead the clinician to reconsider the
antiarrhythmic choice and select a diﬀerent agent or oﬀer
ablationofthearrhythmogenicfocusifanatomicallyfeasible.
For patients unlikely to respond to other antiarrhythmic
therapies, prophylactic thyroid ablation with radioactive
iodine or thyroidectomy might be considered. Another
potential consideration, owing to the relatively high risk
associated with low BMI, might be to weight-adjust the dose
ofamiodaroneinpatientswithlowBMIinordertominimize
the tissue cytotoxicity of the drug. We acknowledge that our
risk prediction index is not yet ready to be used clinically;
it has been derived only and is level 4 evidence as classiﬁed
by McGinn et al. [25]. Validation in an independent patient
populationisrequiredbeforetheindexcanbeusedinclinical
practice.
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